REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of … – PR Newswire (press release)
The Ledger Gazette |
REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of …
PR Newswire (press release) ROCKVILLE, Md., May 2, 2018 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today … Regenxbio (RGNX) Announces FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of … |
